Arena Pharmaceutical (ARNA +1.4%) trades in the green today after earlier disclosing the price...

Arena Pharmaceutical (ARNA +1.4%) trades in the green today after earlier disclosing the price for a 60-day supply of Belviq 10-mg tablets at $199.50. This compares with Vivus' (VVUS +1%) Qsymia, which retails for $160 per month at a medium dose and $220 per month for the higher dose. Analysts note the success of Belviq will largely depend on lower co-payments and broader insurance coverage, which could come in the next two years.

From other sites
Comments (5)
  • gazoo99
    , contributor
    Comments (476) | Send Message
    March 4th.......


    The first day of sales........
    25 Feb 2013, 03:01 PM Reply Like
  • user418
    , contributor
    Comments (264) | Send Message
    Gooooooooooooooo ARNA !!!!!!!!!!!!!!!!!!!!
    25 Feb 2013, 03:10 PM Reply Like
  • tmbrcv
    , contributor
    Comments (26) | Send Message
    Just for clarification, if you read the 8-k, $199.50 is the price that Esai will pay to Arena. Esai will then re-sell it to the pharmacy who will in turn resell it to the patient.
    25 Feb 2013, 05:14 PM Reply Like
  • Sedric
    , contributor
    Comments (2684) | Send Message
    Seeking Alfalfa missed again here. Esai isn't paying $199.50 to ARNA .They will reimburse them 31% of $199.50 for each sale and keep the rest themselves.
    26 Feb 2013, 01:29 AM Reply Like
  • Howard Rich
    , contributor
    Comments (8) | Send Message
    @gazoo99....March 4th ? How do you know ?
    26 Feb 2013, 07:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs